History
A list of downloadable documents created during development.
Appeal
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 November 2015
Published:
26 January 2016
Final appraisal determination
Published:
03 September 2015
Published:
03 September 2015
Appraisal consultation
Published:
19 June 2015
Published:
19 June 2015
Published:
19 June 2015
Published:
19 June 2015
Published:
19 June 2015
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report addendum
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: appendix 1 updated assessment report
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: decision support unit report
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report
Published:
04 September 2013
Published:
22 February 2013
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final protocol
Published:
30 November 2012
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final scope
Published:
30 November 2012
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: equality impact assessment - scoping
Published:
22 November 2012
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final scope (superseded)
Published:
09 November 2012
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final matrix
Published:
09 November 2012
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: provisional matrix
Published:
16 August 2012
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: draft scope
Published:
14 August 2012